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Background: Adverse drug events (ADEs) are one of the most frequent causes of patient harm resulting from
medical interventions, especially among inpatients. This study aimed to evaluate the incidence of ADEs and
characterise them in terms of degree of harm, medication implicated and patient symptoms, at a Brazilian
university hospital.
Methods: This is a retrospective study of chart review. The method, developed by the Institute for Healthcare
Improvement, uses triggers to identify possible ADEs. The study population comprised adult inpatients at least
15 years old. Obstetric patients and those hospitalised for less than 48 hours were excluded. Time spent in the
intensive care unit was not considered for the purposes of this study. Patients were selected on the basis of simple
random sampling of records of patients discharged from January to July 2008. The records selected were reviewed
by a multidisciplinary team. The indicators of ADE incidence were patients with ADEs and ADE rate per 100
patients. Patients with and without ADE were compared in the bivariate analysis. To identify the drugs classes most
often associated with events, the number of prescriptions of each class of drug was related to the number of
events assigned to it.
Results: The 240 inpatients studied were of mean age 50.8 (SD = 20.0) years, and mostly male (63.8%). A total of 44
ADEs were identified in 35 patient records, with 14.6% of patients presenting ADE and a rate of 18.3% ADEs per 100
patients. The most frequent were skin rash and nausea and vomiting, but severe ADEs were also identified. In the
bivariate analysis long hospital stay and use of 10 or more drugs were associated with the occurrence of ADEs
(p-value < 0.01). The drug classes associated with the highest number of events were anti-infective.
Conclusion: About 1/6 of the hospitalized patients in a teaching hospital showed adverse events what is, by itself,
cause for concern. Increased number of prescribed drugs and greater period of hospitalization appear to favour the
occurrence of these events. In the future studies with higher number of patients may offer evidences of the
association.Background
Adverse drug events (ADEs) are among the most fre-
quent adverse events affecting hospital inpatients [1-3].
Percentages of hospital inpatients suffering ADEs range
from 1.6% to 41.4% and the rate, from 1.7 to 51.8 events/
100 admissions. A considerable proportion of such events
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unless otherwise stated.Despite a lack of consensus, important risk factors re-
ported for ADEs include polypharmacy, female sex, ad-
ministration of drugs with narrow therapeutic range,
renal elimination of drug, age >65 years, and administra-
tion of anticoagulants or diuretics [5]. Other risk factors
reported are acute diseases or metabolic disturbances, as
well as use of drugs with low therapeutic indices and
hepatic enzyme inhibitors or inducers [6].
Mechanisms for evaluating and monitoring the safety
of drugs in clinical use are essential in order to prevent or
reduce harm to patients [7]. There are various methods
and techniques for identifying ADEs during hospital stay,l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Giordani et al. BMC Pharmacology and Toxicology 2014, 15:71 Page 2 of 8
http://www.biomedcentral.com/2050-6511/15/1/71including voluntary notification of cases, retrospective or
prospective patient record review, and analysis of adminis-
trative data. An approach to identifying, quantifying and
monitoring ADEs is to use triggers. These correspond to
signs found during patient record review that may relate
to adverse events [8,9].
In Brazil this approach has been used in a few studies
to identify events in general hospitals [10] and special
units [11,12].
Accordingly, the trigger method was used in this study
to evaluate the incidence of ADE and characterise them
in terms of degree of harm, medication implicated and
patient symptoms, at a Brazilian university hospital.
Methods
Study design and population
This is a retrospective study of chart review at a public
teaching hospital in the west of Paraná State in southern
Brazil. The 173-bed hospital offers care to acute patients
in various specialities.
Ethical approval for the study was given by the Ethical
Committee of the State University of West Paraná (039/
2009-CEP).
The study population comprised adult patients at least
15 years old. Obstetric patients and those hospitalised
for less than 48 hours were excluded. Time spent in the
intensive care unit was not considered for the purposes
of this study. Patients were selected on the basis of sim-
ple random sampling of records of patients discharged
from January to July 2008 (n = 1302). The parameters for
calculating sample size were an estimated 15% of pa-
tients with ADEs, 95% confidence level and 10% desired
absolute precision. Sample size calculation was 242.
Review of patient charts was performed with a tool de-
veloped by the Institute of Health Care Improvement
(IHI) which consists of a set of triggers used to identify
possible ADEs. The method is useful to measure the over-
all level of harm from medications in a health care
organization. The trigger tool provides instructions for
conducting a retrospective review of patient records. The
records selected were reviewed to identify the presence of
at least one of the 19 triggers proposed by the IHI [13].
Definition of ADE
ADE was defined as any injury occurring during the pa-
tient’s drug therapy and resulting either from appropriate
care, or from unsuitable or suboptimal care. The definition
encompasses adverse drug reactions and medication er-
rors [14].
Data collection
The patient record review and evaluation were performed
after training with the data collection instruments and in-
struction manuals. The reviewers discussed the methodsand procedures intensively. The definitions of each trigger
and possible associated ADEs were standardised. A pre-
test of patient records not included in the sample helped
standardise the data collection procedures. In addition, the
reviewers were instructed to record any ADE identified
during hospitalisation, even if the event was not associated
with any trigger or was present on patient admission.
Evaluation of the adverse events was conducted in
three stages:
– In the first stage, the following information was
extracted from the patient records: social and
demographic data; drug prescriptions; and
characteristics of the clinical and hospitalisation
histories. The patient records were reviewed in the
following order: laboratory results, drug
prescriptions, and doctors’ and nurses’ clinical
progress notes. Two reviewers (one pharmacy
student and one medical student), working
independently, evaluated each patient record.
Divergences were resolved by a pharmacist with a
background in public health.
– The second stage was performed by a nurse and a
pharmacist and comprised in-depth review of the
records containing triggers. Those where at least
one of these reviewers identified an ADE were
selected for evaluation in the next stage.
– In the third stage, we decided whether ADEs had
occurred. The possible ADE was evaluated by the
participants of the preceding stages, plus a clinician,
in a face-to-face meeting.
Possible associations between events and suspect
drugs were examined according to the drugs’ properties
[15,16], the patient’s clinical condition and the time until
the occurrence of the event. The Naranjo algorithm [17]
was applied to determine the strength of the causal rela-
tionship with the drugs used by the patient and impli-
cated in the occurrence of each ADE. The total scores
allowed us to classify the ADEs as doubtful (< 1), pos-
sible (1–4), probable (5–8) or definite (≥ 9).
The reviewers classified ADEs by degree of harm into
five categories (E-I) [13]. The events were described using
WHO Adverse Reaction Terminology (WHO-ART) [18].
Further information on the method and techniques
employed can be found in a previous publication [19].
Study variables and statistical analysis
The outcome was the ADEs occurring during the hospital
stay. The variables evaluated were: age in years; sex (fe-
male; male); type of admission (acute/emergency; elective);
type of treatment (surgical; clinical); type of discharge
(medical discharge; transfer; death); treatment in intensive
care unit (yes; no); length of stay in days, cut-off point by
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days); hospitalisation cost by tercile (low; middle; high);
Charlson index (0; 1–2; and 3–9); number of drugs used
(1–9; 10 or more); and medical diagnoses.
Drugs were coded according to the first and second
levels of the Anatomical Therapeutic Chemical (ATC)
classification [20]. The probability of association of each
drug class with ADEs was calculated by dividing the
number of times the class was positively related to an
event by the number of prescriptions of each class, and
multiplying by 100.
Co-morbidities – including the primary and secondary
diagnosis from the cover sheet and coded according to the
10th International Classification of Diseases (ICD-10) [21],
plus further co-morbidities identified from the progress
sheets – were examined using the Charlson index [22].
The index evaluates patient severity by the presence of the
following clinical conditions: AIDS, cerebrovascular dis-
ease, congestive heart failure, connective tissue disease, de-
mentia, myocardial infarction, peripheral vascular disease,
peptic ulcer disease, chronic obstructive pulmonary dis-
ease, hemiplegia, cancer, diabetes mellitus (with or without
chronic complications); and liver and/or kidney disease.
The indicators of ADE frequency were: incidence of
patients with ADEs (number of patients with at least
one new ADE/number of patients) and ADE rate per
100 patients (number of new ADEs/number of patients)
with their respective confidence intervals (95% CI). Pa-
tients with and without ADE were compared in the bi-
variate analysis. To identify the drugs classes most often
associated with events, the number of prescriptions of
each class of drug was related to the number of events
assigned to it. To perform this the number of prescrip-
tions of each drug class associated to an ADE was di-
vided by the number of prescriptions of the drug class.
In the descriptive statistical analysis, the continuous
variables were expressed by mean and standard devi-
ation, and the categorical variables, by percentages. The
continuous variables were subjected to the Kolmogorov-
Smirnov test to examine the assumption of normal dis-
tribution. To test the differences between patients with
and without ADEs, bivariate analysis was performed
considering the independent variables. Where appropri-
ate, the T-Student, Chi-square and Fisher’s Exact tests
were performed to compare sub-groups.
Data were processed using EpiData 3.0 and Microsoft
Office Access 2003, and analysed using the statistical
packages SPSS 15.0 for Windows ® (SPSS Inc., Chicago,
IL, U.S.A.) and R version 2.11.1.
Results
Characteristics of participants
The sample calculated comprised 242 patients. Of these
there were nine losses, seven of which were consideredreplaceable (three patients received outpatient treatment
and were not hospitalised; two remained in the ICU
throughout their hospitalisation; one was an obstetric
patient; and one spent less than 48 hours hospitalised).
The other two losses were deemed irreplaceable (patient
records not located). These hospitalisations comprised
238 patients, but two were re-admitted and these were
considered independent events. Thus the final sample
comprised 240 records of patients admitted between
January and July 2008 (corresponding to 2408 patient-
days), whose data were examined.
The primary diagnoses most often found included “in-
jury, poisoning and certain other consequences of external
causes”, followed by “diseases of the digestive system” and
“diseases of the circulatory system”.
The patients’ mean age was 50.8 years, very close to
the median (50 years), and they were predominantly
male (63.8%). In the study sample, most of the patients
(79.6%) were acute or emergency admissions; approxi-
mately 62.0% received surgical treatment and 5.4% died.
Seventy-five percent of the patients were hospitalised for
less than 10 days and mean hospital stay was 10.0 (SD =
12.2) days. In the sample, 60.0% of the patients displayed
no co-morbidities contributing to the Charlson index and
51.7% used, on average, 10 or more different drugs during
their hospitalisation. In the bivariate analysis only long
hospital stay and use of 10 or more drugs were associated
with the occurrence of ADEs (p-value < 0.01) (Table 1).
Incidence and rate of ADEs
A total of 44 ADEs were identified in 35 patient records,
with 14.6% (95% CI 10.1-19.1) of patients presenting
ADE and a rate of 18.3% (95% CI 13.4-23.2) ADEs per
100 patients. Of the 35 patients with ADEs, seven showed
two or more events, with two of them showing three.
Among the ADEs identified, two were not associated with
the triggers (one was increased transaminases from use of
phenytoin and the other was urinary retention from use of
chlorpromazine). Two other events led to patient hospital-
isation and did not enter into the analyses. In nine ADEs,
identification was made possible by the presence of two or
more triggers. One ADE, a skin rash, was identified by
three different triggers: “antiallergics”, “skin rash” and
“abrupt discontinuation of medication”.
Characteristics of ADEs
Using the Naranjo algorithm, 23 (52.3%) of the ADEs were
classified as “possible” and 20 (45.4%), as “probable”. In
one case (2.3%), it was not possible to apply the algorithm.
As regards patient harm produced, 37 events (84.1%)
were classified in category E, as involving temporary
harm requiring intervention, and 4 (9.1%) in category F,
as causing temporary harm and more extended hospital
stay. Three (6.8%) events were classified as H, where the
Table 1 In-patient characteristics by occurrence of






N (%) N (%) N (%)
Total 205 35 240 -




Female 71 (81.6) 16 (18.4) 87 (36.2) 0.208
Male 134 (87.6) 19 (12.4) 153 (63.8)
Nature of the admission
Urgency/emergency 162 (84.8) 29 (15.2) 191 (79.6) 0.603
Elective 43 (87.8) 6 (12.2) 49 (20.4)
Type of treatment 0.09
Surgical 131 (88.5) 17 (11.5) 148 (61.7)
Clinical 74 (80.4) 18 (19.6) 92 (38.3)
Status of discharge
Discharged/transferred 195 (85.9) 32 (14.1) 227 (94.6) 0.290
Death 10 (76.9) 3 (23.1) 13 (5.4)
ICU
Yes 11 (84.6) 2 (15.4) 13 (15.4) 0.933
No 194 (85.5) 33 (14.5) 225 (94.6)
Length of stayb
≤ 10 days 164 (91.1) 16 (8.9) 180 (75.0) <0.001
> 10 days 41 (68.3) 19 (31.1) 60 (25.0)
Cost of hospitalisationc
Low 73 (90.1) 8 (9.9) 81 (33.8) 0.331
Medium 66 (82.5) 14 (17.5) 80 (33.8)
High 66 (83.5) 13 (16.5) 79 (32.9)
Charlson index
0 126 (87.5) 18 (12.5) 144 (60.0) 0.084
1-2 55 (87.3) 8 (12.7) 63 (26.3)
3-9 24 (72.7) 9 (27.3) 33 (13.8)
Number of drugs
1-9 117 (94.4) 7 (5.6) 124 (48.3) <0.001
10 or more 88 (75.9) 28 (24.1) 116 (51.7)
Total 205 35 240 -
aUsing T-Student for comparing mean ages, Chi-square and Fisher’s Exact tests
for comparing categorical variables.
bCut-off by mean (10.0).
cCategorised in tertiles.
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these were hypoglycaemia, cardiac tamponade and over-
sedation.
Table 2 describes the events. The most frequent were
skin rash (8 events), where ranitidine figured prominently
as the attributed drug, and nausea and vomiting (8 events)associated mainly with the use of an opioid (nalbuphine)
and anti-infectives. Severe events affecting other systems
included prolonged hypoglycaemia, cardiac tamponade
and bed fall.
The drug classes associated with the highest number
of events were those used for the nervous system (15),
anti-infectives for systemic use (13) and drugs used to
treat problems of the alimentary tract and metabolism
(10) and blood and blood forming organs (7), as a result
of their being the most prescribed. The drug class most
strongly associated with ADEs was antiparasitic products
(12.5%). The drug sub classes most prescribed were
analgesics, antibacterial for systemic use, antithrombotic
agents and drugs for acid related disorders (Table 3).
The drugs most commonly involved were nalbuphine
(5), heparin (4), ranitidine (4), captopril (2), phenytoin
(2), chlorpromazine (2), morphine (2), moxifloxacin (2),
amphotericin B (2) and omeprazole (2).
Discussion
About on-sixth of inpatients were found to have experi-
enced ADEs, at a mean rate of 18.3 ADEs per 100 patients.
A meta-analysis of observational studies presented esti-
mates of ADE according to the method of identification of
events [23]. In two out of twenty five studies the events
were identified by a similar set of triggers. One of them
was conducted in the United States with six community
hospitals and estimated a rate of 15.0 ADEs per 100 pa-
tients [24]. In the other study, researchers encountered in
a Brazilian hospital a rate of 26.6 ADEs per 100 patients
[10]. Although the event rate in the last study is higher
than ours the proportion of people with ADE estimated by
the authors [10] is similar, around 15%. Some characteris-
tics of the study population and the hospital’s profile may
explain the differences. The differences in rates may be
also attributed to staff education or case mix that may
occur even when comparing data from a single country.
The characteristics of ADEs we focused on were pa-
tient symptoms and degree of harm. Rashes, nausea,
vomiting, pruritus and dizziness accounted for almost
half the events. The profile of ADEs identified in our
study is similar to that identified in a study conducted in
a tertiary care hospital in Northern Brazil, where skin
was found to be the most commonly affected organ sys-
tem. The gastrointestinal system was also among the
three most affected of them [25].
As regards degree of harm, most of the events resulted
in temporary patient harm that required some interven-
tion. Other studies also used the same source to classify
ADEs, which is the National Coordinating Council for
Medication Error Reporting and Prevention Index. They
obtained similar proportions of events of lower degree
of severity, 87% [26] and 79.9% [8]. Life-threatening
events were much less common, as in other studies [24].
Table 2 Adverse drug events (ADEs) and imputed drugs
Description ADEa Number of cases (n = 44) Drugs
Rash 8 Ranitidine. Metronidazole. Cefazolin. Omeprazole. Morphine. Drug undetermined
Nausea and/or vomiting 8 Nalbuphine. Amphotericin B. Omeprazole. Mannitol. Moxifloxacin
Pruritus, rash, and dizziness 4 Tenoxicam. Nalbuphine. Cefalotin
Bleeding (haemoptysis, bleeding
or melena)
4 Warfarin. Heparin. Omeprazole. Amitriptyline. Simvastatin. Heparin
Acetylsalicylic acid. Heparin
Somnolence 2 Chlorpromazine. Phenytoin
Diarrhoea 2 Ampicillin + sulbactam. Lactulose
Tremor 2 Metoclopramide. Moxifloxacin
Cardiac tamponade 1 Heparin
Fall (from bed) 1 Captopril. Hydrochlorothiazide
Seizure 1 Methylprednisolone
Pseudomembranous colitis 1 Cefepime. Clarithromycin
Hypoglycaemia 1 Insulin
Excessive sedation 1 Midazolam
Other 8 Captopril. Furosemide. Nalbuphine, Morphine. Amphotericin B. Sulfamethoxazole +
trimethoprim. Cefepime. Fluconazole. Pentamidine. Phenytoin. Chlorpromazine.
aThe events were described using WHO Adverse Reaction Terminology (WHO-ART).
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keep the patient alive, such as hypoglycemia, cardiac
tamponade and over-sedation, related, respectively, to
the use of insulin, heparin and midazolam.
In our sample, certain classes of drugs are intensively
prescribed and also strongly associated with ADEs (i.e.,
return higher ratios of “related ADEs” to “number of pre-
scriptions”), they were analgesics, antibacterials for systemic
use, antithrombotic agents and drugs for acid-related
disorders. Ranitidine is a drug from this last subclass, as it
is a histamine H2 receptor antagonists, and serves to
illustrate the problem.
Ranitidine was implicated in cases of rash. It was the
most frequent event identified in our study. It was pre-
scribed for 70% of patients, a value compatible with those
found in the literature for use in therapy to suppress gastric
acid production [27,28]. We observed that, in most pa-
tients, ranitidine was being used as prophylactic medication
rather than to treat gastrointestinal diseases. Stress ulcer
prophylaxis has become an increasingly common practice
for clinical patients, although there is little or no clinical
evidence to support it [27] and it can be considered
unnecessary in 73% of cases [28]. According to figures from
this hospital, more than 50% of the ranitidine dispensed is
for intravenous administration, which exposes the patients
to unnecessary risk, because the injection route can cause
local burning, itching, skin rash and vasculitis [15].
The occurrence of ADEs is associated with the number
of drugs used [5,25,29-31]. Our data corroborate that asso-
ciation: the likelihood of an ADE occurring was higher in
users of 10 or more drugs than in those who used fewerdrugs during their hospital stay (p value <0.001), although
the analysis was not adjusted for confounders. When
patients are seriously ill, it is often difficult to evaluate the
degree of harm to be attributed to the number of pre-
scribed drugs or to drug classes. In our study population,
one patient suffered a bed fall during the hospital stay.
Besides the fact that he was exposed to drugs likely to cause
falls (captopril, hydrochlorothiazide), evaluation of the harm
was jeopardised by the complexity of the patient’s condition
(serious traffic accident casualty).
Patients with longer hospital stays are exposed to
greater likelihood of ADE than those hospitalised for up
to nine days (p value <0.001). This finding is consistent
with those of several previous studies [5]. Hence it is
important draw attention to long-stay inpatients, be-
cause in addition to being prone to ADEs, the tendency
is towards multiple events and more pronounced patient
harm.
As longer hospital stays and use of more drugs are
regarded as factors associated with ADEs, our findings may
help physicians to identify at-risk patients and monitor
them carefully. Moreover, to prevent ADES during hospital
stay, the risk factors can be categorised according to oppor-
tunities for intervention, such as decreasing the number of
drugs prescribed or adjusting the dose [32].
This study has limitations in terms of the internal valid-
ity. The results of specific events should be analysed with
caution because the sample size was calculated consider-
ing the estimated global incidence of ADEs. Thus, the
frequency of specific events may reflect random variations
and may be skewed.
Table 3 Drug classes related to an adverse drug event (ADE), by anatomical therapeutic chemical classification (ATC)
ATC codea Number of prescriptionsof the drug class
Number of prescriptions of the drug
class associated with an ADEb Proportion (%)
A - Alimentary tract and metabolism 478 10 2.09
A02 - Drugs for acid related disorders 197 7 3.6
A03 - Drugs for functional gastrointestinal disorders 182 1 0.6
A06 – Laxatives 15 1 6.7
A10 - Drugs used in diabetes 59 1 1.7
B - Blood and blood forming organs 354 7 2.0
B01 - Antithrombotic agents 228 6 2.6
B05 - Plasma substitutes and perfusion solutions 102 1 1.0
C - Cardiovascular system 277 5 1.8
C03 – Diuretics 69 2 2.9
C09 - Agents acting on the renin-angiotensin system 79 2 2.5
C10 - Lipid modifying agents 28 1 3.6
H - Systemic hormonal prep, excluding sex hormones 44 1 2.3
H02 - Corticosteroids for systemic use 44 1 2.3
J - General antiinfectives for systemic use 405 13 3.2
J01 - Antibacterials for systemic use 387 10 2.6
J02 - Antimycotics for systemic use 7 3 42.9
M - Musculo-skeletal system 177 1 0.6
M01 - Antiinflammatory and antirheumatic products 168 1 0.6
N - Nervous system 566 15 2.7
N02 – Analgesics 419 9 1.7
N03 – Antiepileptics 40 2 5.0
N05 – Psycholeptics 82 3 6.1
N06 - Psychoanaleptics 11 1 9.1
P - Antiparasitic products 8 1 12.5
P01 – Antiprotozoals 2 1 50.0
Unclassified drug 9 1 11.1
Total 2499 54 2.2
aThe first and second level of the Anatomical Therapeutic Chemical Classification (ATC) associated with at least one ADE.
bNumber of ADE-drugs is greater (54) than number of ADEs (44), because one drug can be associated with several ADEs.
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serving values of the estimates that differed with statis-
tical significance between patients with or without ADEs
for the variables length of stay and number of medica-
tions in the bivariate analysis. However studies with lar-
ger samples should test the hypothesis of association.
The study was conducted at only one hospital, which
makes external validity troublesome and places limitations
on how far the results can be generalised. Nonetheless,
they may be applied to other tertiary hospitals in medical
schools in Brazil and in other countries.
We endeavoured to increase internal validity by using
double data collection and assembling a team of re-
searchers and health professionals to evaluate the cases.
In order to improve objectivity, the method was appliedat all stages by two independent reviewers, using a spe-
cific manual containing definitions and detailed descrip-
tions of the procedures. Nonetheless, some subjectivity
in identifying and interpreting triggers and events can-
not be ruled out, as demonstrated in other retrospective
patient record review studies [33]. The double-blind
evaluation performed here was not intended to assess
inter-observer reliability, but rather to foster information
completeness and improve validity of the information.
The double evaluation process with two physicians of
patient records to assess ADE is not more reliable than a
record review process with one physician [34].
Poor quality of information in hospital records is a
common problem in chart review-based research [35],
but the choice of a teaching hospital possibly reduces
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pleteness, however. Conspicuous gaps in the recorded
information included race/ethnicity and occupation,
which were missing from about 20% of patient records.
During application of the method, two events unre-
lated to the triggers were identified, one of them a case
of increased blood transaminase levels resulting from
use of phenytoin. Studies have shown that laboratory
test results for transaminases levels can be effective trig-
gers for detecting ADEs. Aspartate aminotransferase
(AST) screening returns a positive predictive value be-
tween 0.01 and 0.23, and alanine aminotransferase
(ALT), a value from 0 to 0.31 [36]. The fact that, in our
study, some ADEs were not found by triggers reinforces
the idea that no single method captures every event that
occurs in hospitals. This challenges managers and policy
makers to test and harmonise different methods to ad-
dress adverse events. The use of triggers to identify ADEs,
when integrated with event monitoring, stimulated or un-
stimulated spontaneous reporting and other techniques,
can be an important strategy for indicating possible short-
comings in the process of using medications for hospita-
lised patients.
According to Rozich [8] the trigger enables organisa-
tions to monitor longitudinally how ADE rates change in
response to strategies designed to improve clinical safety
[8]. However, this strategy is nowadays mainly theoretical,
since there are several obstacles to be overcome, among
them: scant evidence of impact of ongoing strategies; the
existence of different subcategories of drug adverse events
requiring different improvement interventions; the fact
that many common adverse events require more complex
detection strategies [37,38].
The concept of ADE we used included drug adverse
reactions (ADR) and errors. It does not conflict with the
concept of ADR that sustains the algorithm used to de-
termine the strength of the causal relationship with the
drugs in our study and others [39-41]. Steady conceptual
advances in the field of pharmacoepidemiology are per-
mitting studies focussing primarily on occurrences of pa-
tient harm, regardless of whether or not such harm is
associated with errors in therapeutic indication or drug
administration. Besides, examining carefully the patient
charts we did not identified any case of error like non
adherence and subtherapeutic doses.
In 2013 Brazil’s Ministry of Health launched a national
patient safety programme [42]. It hinges on engaging pa-
tients in health care, including the subject of ‘patient
safety’ in undergraduate and postgraduate education,
and increasing research. On this latter item, the
programme specifies measuring harm, understanding
the causes, identifying the solutions, assessing the im-
pact and applying the evidence to assure safer patient
care. Given that framework, we believe the results ofthis study can help to call attention to the need of de-
velop researchs aiming to estimate and characterize
ADE and medication involved as well as the role of
number of drugs prescribed for inpatients.
Conclusion
This study draws attention to the problem of ADE in
hospitalized patients and offers a methodological alter-
native for future research in Brazil as well as other
underdeveloped countries. Our results suggests that trig-
ger tool may be useful to identify ADE in hospitals.
About 1/6 of the hospitalized patients in a teaching
hospital showed adverse events what is, by itself, cause
for concern. Although the events were classified as less
serious in over 80% of cases, we also identified additional
and more severe events that required intervention to
keep the patient alive.
Analgesics, antibacterials for systemic use, antithrom-
botic agents, drugs for acid-related disorders should be
used sparingly, because they are very often prescribed and
associated with the highest numbers of events. These re-
sults should be examined with caution, as the number of
ADE is small (44/240 patients). Increased number of pre-
scribed drugs and greater period of hospitalization appear
to favour the occurrence of these events but additional re-
search should test this hypothesis.
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